Literature DB >> 19690043

New agents and techniques for imaging prostate cancer.

Atif Zaheer1, Steve Y Cho, Martin G Pomper.   

Abstract

The successful management of prostate cancer requires early detection, appropriate risk assessment, and optimum treatment. An unmet goal of prostate cancer imaging is to differentiate indolent from aggressive tumors, as treatment may vary for different grades of the disease. Different modalities have been tested to diagnose, stage, and monitor prostate cancer during therapy. This review briefly describes the key clinical issues in prostate cancer imaging and therapy and summarizes the various new imaging modalities and agents in use and on the horizon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690043      PMCID: PMC3336101          DOI: 10.2967/jnumed.109.061838

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.

Authors:  A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

2.  11C-acetate PET imaging of prostate cancer.

Authors:  Nobuyuki Oyama; Hironobu Akino; Hiroshi Kanamaru; Yuji Suzuki; Satoshi Muramoto; Yoshiharu Yonekura; Norihiro Sadato; Kazutaka Yamamoto; Kenichiro Okada
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

3.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

4.  Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans.

Authors:  Junqian Xu; Peter A Humphrey; Adam S Kibel; Abraham Z Snyder; Vamsidhar R Narra; Joseph J H Ackerman; Sheng-Kwei Song
Journal:  Magn Reson Med       Date:  2009-04       Impact factor: 4.668

5.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

6.  PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.

Authors:  Ursula Elsässer-Beile; Gerald Reischl; Stefan Wiehr; Patrick Bühler; Philipp Wolf; Karen Alt; John Shively; Martin S Judenhofer; Hans-Jürgen Machulla; Bernd J Pichler
Journal:  J Nucl Med       Date:  2009-03-16       Impact factor: 10.057

7.  Challenges in clinical prostate cancer: role of imaging.

Authors:  Gary J Kelloff; Peter Choyke; Donald S Coffey
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

8.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.

Authors:  Mark J Albers; Robert Bok; Albert P Chen; Charles H Cunningham; Matt L Zierhut; Vickie Yi Zhang; Susan J Kohler; James Tropp; Ralph E Hurd; Yi-Fen Yen; Sarah J Nelson; Daniel B Vigneron; John Kurhanewicz
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

9.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.

Authors:  Mukesh G Harisinghani; Jelle Barentsz; Peter F Hahn; Willem M Deserno; Shahin Tabatabaei; Christine Hulsbergen van de Kaa; Jean de la Rosette; Ralph Weissleder
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

10.  Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate.

Authors:  Kenneth N Barton; Hans Stricker; Stephen L Brown; Mohamed Elshaikh; Ibrahim Aref; Mei Lu; Jan Pegg; Yingshu Zhang; Kastytis C Karvelis; Farzan Siddiqui; Jae Ho Kim; Svend O Freytag; Benjamin Movsas
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more
  17 in total

Review 1.  Management of low (favourable)-risk prostate cancer.

Authors:  H Ballentine Carter
Journal:  BJU Int       Date:  2011-12       Impact factor: 5.588

2.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

3.  An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.

Authors:  Eric J Lepin; Jeffrey V Leyton; Yu Zhou; Tove Olafsen; Felix B Salazar; Katelyn E McCabe; Scott Hahm; James D Marks; Robert E Reiter; Anna M Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-01       Impact factor: 9.236

Review 4.  The evolution of imaging in cancer: current state and future challenges.

Authors:  Luke J Higgins; Martin G Pomper
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 5.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).

Authors:  Brice A P Wilson; Haofan Wang; Benjamin A Nacev; Ronnie C Mease; Jun O Liu; Martin G Pomper; William B Isaacs
Journal:  Mol Cancer Ther       Date:  2011-03-25       Impact factor: 6.261

Review 7.  Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Authors:  Phillip J Koo; Jennifer J Kwak; Sajal Pokharel; Peter L Choyke
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 8.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

9.  Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.

Authors:  Yuping Xu; Donghui Pan; Chen Zhu; Qing Xu; Lizhen Wang; Fei Chen; Runlin Yang; Shineng Luo; Min Yang; Yongjun Yan
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

10.  Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin.

Authors:  Chang-Moon Lee; Hwan-Jeong Jeong; Su-Jin Cheong; Eun-Mi Kim; Dong Wook Kim; Seok Tae Lim; Myung-Hee Sohn
Journal:  Pharm Res       Date:  2010-02-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.